Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements
July 7th, 2025
News
All Categories
ACDL
APDN in the News
CertainT®
Coronavirus
Corporate/Financial News
Investors
Large-Scale DNA Production
Linear DNA
mpox
PGx
Press Release
Uncategorized
Vaccines
Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx
June 30th, 2025
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
June 17th, 2025
Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3’25 Financial Results Report in Mid-August
June 16th, 2025
Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17
May 29th, 2025
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
May 29th, 2025
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
May 15th, 2025
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
May 14th, 2025
Applied DNA’s LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
April 21st, 2025